Acuvail receives FDA approval
Allergan Inc has received the FDA approval for its post-cataract surgery eye solution Acuvail (ketorolac tromethamine ophthalmic solution). The eye solution is aimed at treating pain and inflammation following cataract surgery. Allergan said that more than 3 million cataract surgeries are performed in the US every year. Acuvail is expected to reach the market in September.- Allergan receives approval for Ozurdex
- FDC receives FDA approval for Timolol Maleate Ophthalmic Solution
- Bausch & Lomb’s pink eye drug likely to get FDA recommendation
- CHMP recommends Azarga for approval
